

21<sup>st</sup> August, 2006

## Press Release

### **The Genetics Company Inc. renews Long Term Supply Agreement with JSW-Research Ltd.**

The Genetics Company, Inc. a privately held Swiss company focusing on the research, development and commercialization of products for the diagnosis, monitoring and therapy of patients suffering from Alzheimer's disease and cancer announces the renewal of the existing long term supply agreement with JSW-Research Ltd. a leading Austrian contract research organization. Within the scope of this agreement, The Genetics Company, Inc. is supplying JSW-Research Ltd. with its highly sensitive and specific test kits for quantification of human beta-Amyloid (A $\beta$ ) in Alzheimer's disease (AD) pre-clinical and clinical research for another three years.

Please find enclosed our press release. Thank you for your consideration and kind regards,



Dr. Harald Eistetter, CEO  
[eistetter@the-genetics.com](mailto:eistetter@the-genetics.com)

[www.the-genetics.com](http://www.the-genetics.com)

## PRESS RELEASE

Zurich, Switzerland – 21<sup>st</sup> August, 2006

### **The Genetics Company Inc. renews Long Term Supply Agreement with JSW-Research Ltd.**

The Genetics Company, Inc., a privately held Swiss company focusing on the research, development and commercialization of products for the diagnosis, monitoring and therapy of patients suffering from Alzheimer's disease and cancer, announces the renewal of the existing long term supply agreement with JSW-Research Ltd., an Austrian based leading contract research organization with special expertise in neurodegenerative diseases. The successful cooperation between The Genetics Company and JSW-Research over the last three years was decisive for both Companies to prolong the agreement. Within the scope of this agreement, The Genetics Company, Inc. is supplying JSW-Research Ltd. with enzyme-linked immunosorbent assay (ELISA) based test kits for their Alzheimer's disease (AD) pre-clinical and clinical contract research for another three years.

The Genetics Company's ELISA test kits enable the specific and reliable detection of two variants of human beta-Amyloid (A $\beta$ ), A $\beta$ 42 and A $\beta$ 40. A $\beta$  is a key protein associated with the pathogenesis of several neurodegenerative diseases such as AD and stroke. The A $\beta$ 42/40 ratio has been validated as highly sensitive and specific biomarker for diagnosis of incipient AD. Furthermore, the test kits are used in clinical trials as drug monitoring tools or for efficacy studies of beta-Amyloid lowering drugs in animal models.

Dr. Manfred Windisch, CEO and President of JSW-Research Ltd. said: "We are very pleased being able to continue our excellent cooperation with The Genetics Company. Their top quality human beta-Amyloid test kits are more than a decisive support of and complementation to our services and own research programs". Dr. Sebastian Breuer, Program Manager Diagnostics at The Genetics Company added: "It is a great pleasure for us to extend our fruitful collaboration with JSW thereby supporting one of the few recognized world leaders in clinical and preclinical Alzheimer's research".

### **About JSW-Research Ltd.**

JSW-Research Ltd., Graz, Austria, offers comprehensive research and consulting programs for drug development concerning disorders of the central nervous system. JSW-Research uses modern molecular biology techniques and has also designed a variety of disease relevant cell and animal models for characterizing drug effects. Interlacing modular systems facilitate step-by-step analysis of candidate substances from basic in vitro to complex in vivo assays, complemented by a full range of histological, biochemical and behavioral evaluation methods. Years of experience in neuropharmacology have also established the company as an expert in clinical research. JSW-Research Ltd. plans clinical development programs and monitors clinical studies throughout all phases for neurodegenerative disorders as well as a broad range of other diseases

**About The Genetics Company, Inc.**

The Genetics Company, Inc. is a dedicated team of entrepreneurs and scientists focusing on the research, development and commercialization of innovative products for the diagnosis, therapy and therapy monitoring of patients suffering from neurodegenerative disease and cancer. Apart from a set of worldwide unique diagnostic kits and tools for the diagnosis and monitoring of patients suffering from Alzheimer's disease (AD), the Company has identified small molecule inhibitors of BACE (beta-Amyloid converting enzyme). It has also identified small molecule inhibitors of two proprietary targets within the Wnt-pathway, which is believed to play a crucial role in colon cancer. Headquartered in Zurich-Schlieren, Switzerland, the Company currently has 25 employees.

*For additional information about JSW-Research Ltd please contact:*

**Dr. Manfred Windisch**  
**JSW-Research Forschungslabor GmbH**  
**Rankengasse 28**  
**8020 Graz**  
**Austria**  
**Tel: +43-316-76511411**  
**Fax: +43-316-7651144**  
**E-mail: [mwindisch@jswresearch.com](mailto:mwindisch@jswresearch.com)**  
**Web: [www.jswresearch.com](http://www.jswresearch.com)**

*For corporate information about The Genetics Company please contact:*

**Dr. Harald Eistetter**  
**The Genetics Company**  
**Wagistrasse 27**  
**CH-8952 Schlieren/Zürich**  
**Switzerland**  
**Tel: +41-44-2002222**  
**Fax: +41-44-2002211**  
**E-mail: [eistetter@the-genetics.com](mailto:eistetter@the-genetics.com)**  
**Web: [www.the-genetics.com](http://www.the-genetics.com)**

*For further information about The Genetics Company's diagnostic products please contact:*

**Oliver Wildanger**  
**The Genetics Company**  
**Tel: +41-44-2002266:**  
**E-mail: [wild@the-genetics.com](mailto:wild@the-genetics.com)**